{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:16:47Z","timestamp":1792700207099,"version":"4.5.0"},"reference-count":163,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["D.O.NO.BT\/HRD\/35\/02\/2006"],"award-info":[{"award-number":["D.O.NO.BT\/HRD\/35\/02\/2006"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/RLF\/Re-entry 66\/2017"],"award-info":[{"award-number":["BT\/RLF\/Re-entry 66\/2017"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["GAP-39"],"award-info":[{"award-number":["GAP-39"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.micpath.2024.107074","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T12:54:20Z","timestamp":1730984060000},"page":"107074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Advancements and challenges in tuberculosis drug discovery: A comprehensive overview"],"prefix":"10.1016","volume":"198","author":[{"given":"Puja Kumari","family":"Agnivesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnab","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashikanta","family":"Sau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4346-6567","authenticated-orcid":false,"given":"Nitin Pal","family":"Kalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.micpath.2024.107074_bib2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3390\/antibiotics12010166","article-title":"First and second-line anti-tuberculosis drug-resistance patterns in pulmonary tuberculosis patients in Zambia","volume":"12","author":"Monde","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.micpath.2024.107074_bib3","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.2147\/IDR.S408976","article-title":"Mycobacterium tuberculosis intra-host evolution among drug-resistant tuberculosis patients failing treatment","volume":"16","author":"Perumal","year":"2023","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.micpath.2024.107074_bib4","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.ijid.2023.03.013","article-title":"Update of drug-resistant tuberculosis treatment guidelines: a turning point","volume":"130","author":"Vanino","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.micpath.2024.107074_bib5","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1016\/S2666-5247(20)30195-6","article-title":"Globally diverse Mycobacterium tuberculosis resistance acquisition: a retrospective geographical and temporal analysis of whole genome sequences","volume":"2","author":"Ektefaie","year":"2021","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.micpath.2024.107074_bib6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/13993003.00724-2015","article-title":"Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis","volume":"47","author":"Pym","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.micpath.2024.107074_bib7","series-title":"Innovations and Implementations of Computer Aided Drug Discovery Strategies in Rational Drug Design","first-page":"295","article-title":"Molecular dynamics simulation in drug discovery: opportunities and challenges","author":"Shukla","year":"2021"},{"key":"10.1016\/j.micpath.2024.107074_bib8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/17460441.2021.1854221","article-title":"Drug development post COVID-19 pandemic: toward a better system to meet current and future global health challenges","volume":"16","author":"Aghila Rani","year":"2021","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.micpath.2024.107074_bib9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.chom.2020.11.013","article-title":"The immune landscape in tuberculosis reveals populations linked to disease and latency","volume":"29","author":"Esaulova","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.micpath.2024.107074_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310482","article-title":"Target identification in anti-tuberculosis drug discovery","volume":"24","author":"Capela","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.micpath.2024.107074_bib11","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1365-2672.2009.04161.x","article-title":"Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment","volume":"107","author":"Falkinham","year":"2009","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.micpath.2024.107074_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2021.112405","article-title":"Tanshinones from Salvia miltiorrhiza inhibit Mycobacterium tuberculosis via disruption of the cell envelope surface and oxidative stress","volume":"156","author":"Sieniawska","year":"2021","journal-title":"Food Chem. Toxicol."},{"issue":"1 11","key":"10.1016\/j.micpath.2024.107074_bib13","first-page":"1","article-title":"Survival of hypoxia-induced dormancy is not a common feature of all strains of the Mycobacterium tuberculosis complex","volume":"11","author":"Tizzano","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.micpath.2024.107074_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2020.102047","article-title":"Human monocyte-derived macrophage responses to M. tuberculosis differ by the host's tuberculosis, diabetes or obesity status, and are enhanced by rapamycin","volume":"126","author":"Restrepo","year":"2021","journal-title":"Tuberculosis"},{"key":"10.1016\/j.micpath.2024.107074_bib15","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.cell.2014.11.024","article-title":"Host evasion and exploitation schemes of Mycobacterium tuberculosis","volume":"159","author":"Cambier","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.micpath.2024.107074_bib16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3389\/fimmu.2021.636078","article-title":"Better together: current insights into phagosome-lysosome fusion","volume":"12","author":"Nguyen","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2024.107074_bib17","article-title":"Clinically relevant mutations in core metabolic genes confer antibiotic resistance","author":"Lopatkin","year":"2021","journal-title":"Science.Sciencemag.Org"},{"key":"10.1016\/j.micpath.2024.107074_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.mib.2023.102334","article-title":"Counteracting antibiotic resistance enzymes and efflux pumps","volume":"75","author":"Zheng","year":"2023","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.micpath.2024.107074_bib19","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ceramint.2020.08.201","article-title":"Graphene nanoplatelets\/Cr2O3 nanocomposites as novel nanoantibiotics: towards control of multiple drug resistant bacteria","volume":"47","author":"Talat","year":"2021","journal-title":"Ceram. Int."},{"key":"10.1016\/j.micpath.2024.107074_bib20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2174\/1574885515666200722150305","article-title":"Quality-by-design enabled chitosan nanoparticles for antitubercular therapy: formulation, statistical optimization, and in vitro characterization","volume":"16","author":"Chogale","year":"2020","journal-title":"Curr. Drug Ther."},{"key":"10.1016\/j.micpath.2024.107074_bib21","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1126\/science.aax3879","article-title":"The evolution of antibiotic resistance","volume":"365","author":"MacLean","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.micpath.2024.107074_bib22","doi-asserted-by":"crossref","first-page":"e3937","DOI":"10.1093\/cid\/ciaa617","article-title":"Who knew? Injectable TB drugs are not equal, despite drug susceptibility testing","volume":"73","author":"Hamilton","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.micpath.2024.107074_bib23","first-page":"90","article-title":"Adherence and perception of care among patients with multidrug resistant tuberculosis in north Central Nigeria","volume":"6","author":"Madukaji","year":"2021","journal-title":"Article.Ijoidt.Org"},{"key":"10.1016\/j.micpath.2024.107074_bib24","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/jac\/dkr261","article-title":"The urgent need for new antibacterial agents","volume":"66","author":"Wise","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.micpath.2024.107074_bib25","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(19)30024-8","article-title":"Building a tuberculosis-free world: the Lancet Commission on tuberculosis","volume":"393","author":"Reid","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.micpath.2024.107074_bib81","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/13543776.2021.1902990","article-title":"Synthetic molecules as DprE1 inhibitors: a patent review","volume":"31","author":"Imran","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.micpath.2024.107074_bib82","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/emmm.201303575","article-title":"Towards a new combination therapy for tuberculosis with next generation benzothiazinones","volume":"6","author":"Makarov","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.micpath.2024.107074_bib83","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1128\/AAC.00778-15","article-title":"The 8-pyrrole-benzothiazinones are noncovalent inhibitors of DprE1 from Mycobacterium tuberculosis","volume":"59","author":"Makarov","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2024.107074_bib84","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1021\/jm500571f","article-title":"Lead optimization of 1,4-azaindoles as antimycobacterial agents","volume":"57","author":"Shirude","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib85","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1021\/acs.jmedchem.1c00263","article-title":"Discovery of novel thiophene-arylamide derivatives as DprE1 inhibitors with potent antimycobacterial activities","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib86","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1021\/jm5005978","article-title":"4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity","volume":"57","author":"Naik","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib87","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1021\/jm5002937","article-title":"Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity","volume":"57","author":"Panda","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.611304","article-title":"Tuberculosis drug discovery: a decade of hit assessment for defined targets","volume":"11","author":"Oh","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.micpath.2024.107074_bib89","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/chir.22806","article-title":"Lipase-catalyzed kinetic resolution of novel antitubercular benzoxazole derivatives","volume":"30","author":"\u0141ukowska-Chojnacka","year":"2018","journal-title":"Chirality"},{"key":"10.1016\/j.micpath.2024.107074_bib90","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1128\/AAC.01601-09","article-title":"In vitro interactions between new antitubercular drug candidates SQ109 and TMC207","volume":"54","author":"Reddy","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2024.107074_bib91","author":"Mcneil"},{"key":"10.1016\/j.micpath.2024.107074_bib92","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1021\/acs.jmedchem.6b00415","article-title":"Indole-2-carboxamide-based MmpL3 inhibitors show exceptional antitubercular activity in an animal model of tuberculosis infection","volume":"59","author":"Stec","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib93","volume":"10","author":"Remui\u00f1","year":"2013","journal-title":"V. nica Sousa, pone.0060933 1"},{"key":"10.1016\/j.micpath.2024.107074_bib94","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00706-019-02457-9","article-title":"Design, synthesis, antitubercular and antiviral properties of new spirocyclic indole derivatives","volume":"150","author":"Cihan-\u00dcst\u00fcnda\u011f","year":"2019","journal-title":"Monatsh. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib95","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1016\/j.bmc.2017.07.034","article-title":"Discovery of new leads against Mycobacterium tuberculosis using scaffold hopping and shape based similarity","volume":"25","author":"Wavhale","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib39","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.drudis.2016.09.009","article-title":"A new \u2018golden age\u2019for the antitubercular target InhA","volume":"22","author":"Ro\u017eman","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.micpath.2024.107074_bib97","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.trsl.2020.03.007","article-title":"New tuberculosis drug targets, their inhibitors, and potential therapeutic impact","volume":"220","author":"Shetye","year":"2020","journal-title":"Transl. Res."},{"key":"10.1016\/j.micpath.2024.107074_bib98","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.3c01514","article-title":"Identification and optimization of novel inhibitors of the polyketide synthase 13 thioesterase domain with antitubercular activity","author":"Green","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114066","article-title":"Tuberculosis drug discovery: progression and future interventions in the wake of emerging resistance","volume":"229","author":"Perveen","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib100","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00165-18","article-title":"Comparison of in vitro activity and MIC distributions between the novel oxazolidinone delpazolid and linezolid against multidrug-resistant and extensively drug-resistant mycobacterium tuberculosis in China","volume":"62","author":"Zong","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2024.107074_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128824","article-title":"Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agent","volume":"71","author":"Huang","year":"2022","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.micpath.2024.107074_bib102","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1021\/ml300134b","article-title":"Quinolinyl pyrimidines: potent inhibitors of NDH-2 as a novel class of anti-TB agents","volume":"3","author":"Shirude","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.micpath.2024.107074_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.611304","article-title":"Tuberculosis drug discovery: a decade of hit assessment for defined targets","volume":"11","author":"Oh","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.micpath.2024.107074_bib104","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1021\/acsinfecdis.7b00275","article-title":"2-Mercapto-Quinazolinones as inhibitors of type II NADH dehydrogenase and Mycobacterium tuberculosis: structure-activity relationships, mechanism of action and absorption, distribution, metabolism, and excretion characterization","volume":"4","author":"Murugesan","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.micpath.2024.107074_bib56","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1002\/anie.201800260","article-title":"Small molecules targeting Mycobacterium tuberculosis type II NADH dehydrogenase exhibit antimycobacterial activity","volume":"57","author":"Harbut","year":"2018","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.micpath.2024.107074_bib105","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/157340609787582882","article-title":"MenA is a promising drug target for developing novel lead molecules to combat Mycobacterium tuberculosis","volume":"5","author":"Kurosu","year":"2009","journal-title":"Med. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib106","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1021\/jm201608g","article-title":"Discovery of selective menaquinone biosynthesis inhibitors against Mycobacterium tuberculosis","volume":"55","author":"Debnath","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib107","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ejmech.2015.07.001","article-title":"Combating highly resistant emerging pathogen Mycobacterium abscessus and Mycobacterium tuberculosis with novel salicylanilide esters and carbamates","volume":"101","author":"Baranyai","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112773","article-title":"Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents","volume":"208","author":"Liu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib27","doi-asserted-by":"crossref","first-page":"13011","DOI":"10.1002\/anie.201707324","article-title":"Determinants of the inhibition of DprE1 and CYP2C9 by antitubercular thiophenes","volume":"56","author":"Liu","year":"2017","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.micpath.2024.107074_bib28","doi-asserted-by":"crossref","first-page":"6451","DOI":"10.1128\/AAC.01523-16","article-title":"Characterization of DprE1-mediated benzothiazinone resistance in Mycobacterium tuberculosis","volume":"60","author":"Foo","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2024.107074_bib29","article-title":"Virtual screening of small molecular inhibitors against DprE1","volume":"23","author":"Zhang","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.micpath.2024.107074_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.04721-22","article-title":"Discovery of novel reversible inhibitor of DprE1 based on benzomorpholine for the treatment of tuberculosis","author":"Xiang","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.micpath.2024.107074_bib31","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.gene.2014.11.017","article-title":"Revisiting the essentiality of glutamate racemase in Mycobacterium tuberculosis","volume":"555","author":"Morayya","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.micpath.2024.107074_bib32","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00253-018-9518-z","article-title":"Ethambutol targets the glutamate racemase of Mycobacterium tuberculosis-an enzyme involved in peptidoglycan biosynthesis","volume":"103","author":"Pawar","year":"2019","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.micpath.2024.107074_bib33","doi-asserted-by":"crossref","first-page":"28559","DOI":"10.1074\/jbc.M115.683797","article-title":"Structural basis for the regulation of the MmpL transporters of Mycobacterium tuberculosis","volume":"290","author":"Delmar","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib34","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/mmi.13306","article-title":"Mechanistic insight into mycobacterial MmpL protein function","volume":"99","author":"Sz\u00e9kely","year":"2016","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.micpath.2024.107074_bib35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1515\/hsz-2019-0326","article-title":"Transport mechanism of Mycobacterium tuberculosis MmpL\/S family proteins and implications in pharmaceutical targeting","volume":"401","author":"Ma","year":"2020","journal-title":"Biol. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117212","article-title":"Targeting mycobacterial membranes and membrane proteins: progress and limitations","author":"Kumar","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/srep46696","article-title":"Functional, thermodynamics, structural and biological studies of in silico-identified inhibitors of Mycobacterium tuberculosis enoyl-ACP(CoA) reductase enzyme","volume":"7","author":"Martinelli","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.micpath.2024.107074_bib38","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ejmech.2018.01.047","article-title":"An overview on crystal structures of InhA protein: apo-form, in complex with its natural ligands and inhibitors","volume":"146","author":"Chollet","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2019.144082","article-title":"Structural insight into conformational dynamics of non-active site mutations in KasA: a Mycobacterium tuberculosis target protein","volume":"720","author":"Jayaraman","year":"2019","journal-title":"Gene"},{"key":"10.1016\/j.micpath.2024.107074_bib41","doi-asserted-by":"crossref","DOI":"10.1021\/acsinfecdis.9b00493","article-title":"Exploring the SAR of the \u03b2-ketoacyl-ACP synthase inhibitor GSK3011724A and optimization around a genotoxic metabolite","volume":"6","author":"Cunningham","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.micpath.2024.107074_bib42","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02101-17","article-title":"Synergistic lethality of a binary inhibitor of Mycobacterium tuberculosis KasA","volume":"9","author":"Kumar","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.micpath.2024.107074_bib43","doi-asserted-by":"crossref","first-page":"7014","DOI":"10.1038\/s41598-023-34222-8","article-title":"An integrated computational approach towards novel drugs discovery against polyketide synthase 13 thioesterase domain of Mycobacterium tuberculosis","volume":"13","author":"Altharawi","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.micpath.2024.107074_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113202","article-title":"Design and synthesis of mycobacterial pks13 inhibitors: conformationally rigid tetracyclic molecules","volume":"213","author":"Zhang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105110","article-title":"Identification of inhibitors targeting polyketide synthase 13 of Mycobacterium tuberculosis as antituberculosis drug leads","volume":"114","author":"Wang","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115702","article-title":"Targeting polyketide synthase 13 for the treatment of tuberculosis","author":"Xia","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib47","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.tube.2018.08.005","article-title":"In silico designing of domain B selective gyrase inhibitors for effective treatment of resistant tuberculosis","volume":"112","author":"Kashyap","year":"2018","journal-title":"Tuberculosis"},{"key":"10.1016\/j.micpath.2024.107074_bib48","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01321-21","article-title":"In vitro resistance against DNA gyrase inhibitor SPR719 in Mycobacterium avium and Mycobacterium abscessus","author":"Aragaw","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.micpath.2024.107074_bib49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.01208-21","article-title":"First-in-human evaluation of the safety, tolerability, and pharmacokinetics of SPR720, a novel oral bacterial DNA gyrase (GyrB) inhibitor for mycobacterial infections","volume":"65","author":"Talley","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2024.107074_bib50","doi-asserted-by":"crossref","DOI":"10.1128\/ecosalplus.esp-0017-2019","article-title":"Inhibition of RNA polymerase by rifampicin and rifamycin-like molecules","volume":"9","author":"Mosaei","year":"2020","journal-title":"EcoSal Plus"},{"key":"10.1016\/j.micpath.2024.107074_bib138","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"17","author":"Gillespie","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2024.107074_bib51","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1128\/JB.06128-11","article-title":"Inhibition of Mycobacterium tuberculosis RNA polymerase by binding of a Gre factor homolog to the secondary channel","volume":"194","author":"China","year":"2012","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.micpath.2024.107074_bib52","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02520-18","article-title":"Possible binding of piperine in Mycobacterium tuberculosis RNA polymerase and rifampin synergism","volume":"63","author":"Murase","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2024.107074_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2021.101002","article-title":"Protein synthesis in Mycobacterium tuberculosis as a potential target for therapeutic interventions","volume":"81","author":"Kumar","year":"2021","journal-title":"Mol. Aspect. Med."},{"key":"10.1016\/j.micpath.2024.107074_bib54","doi-asserted-by":"crossref","first-page":"6271","DOI":"10.1128\/AAC.01339-16","article-title":"Discovery of novel oral protein synthesis inhibitors of mycobacterium tuberculosis that target leucyl-tRNA synthetase","volume":"60","author":"Palencia","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2024.107074_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12956-2","article-title":"Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development","volume":"10","author":"Beites","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.micpath.2024.107074_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112420","article-title":"Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors","volume":"201","author":"Nizi","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib58","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02661-18","article-title":"Novel MenA inhibitors are bactericidal against Mycobacterium tuberculosis and synergize with electron transport chain inhibitors","volume":"63","author":"Berube","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2024.107074_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214958","article-title":"Characterization of MenA (isoprenyl diphosphate:1,4-dihydroxy-2-naphthoate isoprenyltransferase) from Mycobacterium tuberculosis","volume":"14","author":"Dhiman","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.micpath.2024.107074_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115125","article-title":"SAR study of piperidine derivatives as inhibitors of 1, 4-dihydroxy-2-naphthoate isoprenyltransferase (MenA) from Mycobacterium tuberculosis","volume":"249","author":"Berg","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-44887-9","article-title":"Carbon metabolism modulates the efficacy of drugs targeting the cytochrome bc 1:aa 3 in Mycobacterium tuberculosis","volume":"9","author":"Kalia","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.micpath.2024.107074_bib62","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00606-19","article-title":"Identification of 4-amino-thieno[2,3- d]Pyrimidines as QcrB inhibitors in Mycobacterium tuberculosis","volume":"4","author":"Harrison","year":"2019","journal-title":"mSphere"},{"key":"10.1016\/j.micpath.2024.107074_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2022.108347","article-title":"Investigation of protein-ligand binding motions through protein conformational morphing and clustering of cytochrome bc1-aa3 super complex","volume":"118","author":"Sindhu","year":"2023","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.micpath.2024.107074_bib64","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jsb.2018.10.006","article-title":"Structure and function of Mycobacterium-specific components of F-ATP synthase subunits \u03b1 and \u03b5","volume":"204","author":"Bogdanovi\u0107","year":"2018","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.micpath.2024.107074_bib65","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.tube.2017.10.008","article-title":"Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis","volume":"108","author":"Kumar","year":"2018","journal-title":"Tuberculosis"},{"key":"10.1016\/j.micpath.2024.107074_bib66","doi-asserted-by":"crossref","first-page":"13295","DOI":"10.1002\/anie.202002546","article-title":"Discovery of a novel mycobacterial F-ATP synthase inhibitor and its potency in combination with diarylquinolines","volume":"59","author":"Hotra","year":"2020","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.micpath.2024.107074_bib67","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75799-8","article-title":"Demystifying the catalytic pathway of Mycobacterium tuberculosis isocitrate lyase","volume":"10","author":"Ibeji","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.micpath.2024.107074_bib68","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1021\/acschembio.0c00740","article-title":"Covalent inactivation of Mycobacterium tuberculosis isocitrate lyase by cis-2,3-epoxy-succinic acid","volume":"16","author":"Pham","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.micpath.2024.107074_bib69","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijbiomac.2015.04.005","article-title":"Isocitrate lyase of Mycobacterium tuberculosis is inhibited by quercetin through binding at N-terminus","volume":"78","author":"Shukla","year":"2015","journal-title":"Int. J. Biol. Macromol."},{"issue":"1 9","key":"10.1016\/j.micpath.2024.107074_bib70","first-page":"1","article-title":"Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials","volume":"9","author":"Korbee","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.micpath.2024.107074_bib71","author":"Sogi"},{"issue":"1 18","key":"10.1016\/j.micpath.2024.107074_bib72","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11302-021-09838-y","article-title":"Purinergic modulation of the immune response to infections","volume":"18","author":"Eberhardt","year":"2022","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.micpath.2024.107074_bib73","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3389\/fcimb.2017.00347","article-title":"Purinergic signaling: a common path in the macrophage response against Mycobacterium tuberculosis and Toxoplasma gondii","volume":"7","author":"Petit-Jentreau","year":"2017","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.micpath.2024.107074_bib74","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cellimm.2007.02.001","article-title":"P2X7 purinergic receptors and extracellular ATP mediate apoptosis of human monocytes\/macrophages infected with Mycobacterium tuberculosis reducing the intracellular bacterial viability","volume":"244","author":"Placido","year":"2006","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.micpath.2024.107074_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008312","article-title":"TNF-\u03b1 antagonists differentially induce TGF-\u03b21-dependent resuscitation of dormant-like Mycobacterium tuberculosis","volume":"16","author":"Arbu\u00e9s","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.micpath.2024.107074_bib76","first-page":"376","article-title":"Tumor necrosis factor induces pathogenic mitochondrial ROS in tuberculosis through reverse electron transport","author":"Roca","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.micpath.2024.107074_bib77","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/cid\/ciab144","article-title":"CD38+CD27\u2013TNF-\u03b1 + on mtb-specific CD4+ T cells is a robust biomarker for tuberculosis diagnosis","volume":"73","author":"Acharya","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.micpath.2024.107074_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120614","article-title":"Differential expression of genes regulated by the glucocorticoid receptor pathway in patients with pulmonary tuberculosis","volume":"301","author":"Gallucci","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.micpath.2024.107074_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107215","article-title":"B and T lymphocyte attenuator regulates autophagy in mycobacterial infection via the AKT\/mTOR signal pathway","volume":"91","author":"Liu","year":"2021","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.micpath.2024.107074_bib80","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00253-21","article-title":"Dual mTORC1\/mTORC2 inhibition as a host-directed therapeutic target in pathologically distinct mouse models of tuberculosis","volume":"65","author":"Tasneen","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2024.107074_bib108","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01991-21","article-title":"Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: despite progress, more action is needed","volume":"66","author":"Butler","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2024.107074_bib109","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.drudis.2020.11.026","article-title":"Desirable drug\u2013drug interactions or when a matter of concern becomes a renewed therapeutic strategy","volume":"26","author":"Guieu","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.micpath.2024.107074_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105804","article-title":"Selectively targeting individual bromodomain: drug discovery and molecular mechanisms","volume":"172","author":"Wang","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.micpath.2024.107074_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113853","article-title":"Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins","volume":"226","author":"Fu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib112","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pbiomolbio.2019.11.006","article-title":"Unique structural and mechanistic properties of mycobacterial F-ATP synthases: implications for drug design","volume":"152","author":"Kamariah","year":"2020","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.micpath.2024.107074_bib113","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.3390\/app10072339","article-title":"Oxidative phosphorylation\u2014an update on a new, essential target space for drug discovery in Mycobacterium tuberculosis","volume":"10","author":"Foo","year":"2020","journal-title":"Appl. Sci."},{"key":"10.1016\/j.micpath.2024.107074_bib114","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.3390\/app10072269","article-title":"Development of macozinone for TB treatment: an update","volume":"10","author":"Makarov","year":"2020","journal-title":"Appl. Sci."},{"key":"10.1016\/j.micpath.2024.107074_bib115","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00840-18","article-title":"Optimized background regimen for treatment of active tuberculosis with the next-generation benzothiazinone macozinone (PBTZ169)","volume":"62","author":"Lupien","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7 79","key":"10.1016\/j.micpath.2024.107074_bib116","first-page":"1","article-title":"Identification of mutations associated with macozinone-resistant in Mycobacterium tuberculosis","volume":"79","author":"Chen","year":"2022","journal-title":"Curr. Microbiol."},{"key":"10.1016\/j.micpath.2024.107074_bib117","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.3390\/app10072211","article-title":"Development of delpazolid for the treatment of tuberculosis","volume":"10","author":"Cho","year":"2020","journal-title":"Appl. Sci."},{"key":"10.1016\/j.micpath.2024.107074_bib118","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094462","article-title":"Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis","volume":"9","author":"Wallis","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.micpath.2024.107074_bib119","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02108-21","article-title":"Single ascending-dose study to evaluate the safety, tolerability, and pharmacokinetics of sutezolid in healthy adult subjects","volume":"66","author":"Bruinenberg","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2024.107074_bib120","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1128\/AAC.01920-13","article-title":"Population pharmacokinetic\/pharmacodynamic analysis of the bactericidal activities of sutezolid (pnu-100480) and its major metabolite against intracellular mycobacterium tuberculosis in ex vivo whole-blood cultures of patients with pulmonary tuberculosis","volume":"58","author":"Zhu","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2024.107074_bib121","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1183\/09031936.00162314","article-title":"Novel drugs against tuberculosis: a clinician's perspective","volume":"45","author":"Olaru","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.micpath.2024.107074_bib122","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01655-22","article-title":"Side-by-Side profiling of oxazolidinones to estimate the therapeutic window against mycobacterial infections","volume":"67","author":"Negatu","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2024.107074_bib123","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.3390\/app10072278","article-title":"Mycobacterial cell wall: a source of successful targets for old and new drugs","volume":"10","author":"Vilch\u00e8ze","year":"2020","journal-title":"Appl. Sci."},{"key":"10.1016\/j.micpath.2024.107074_bib124","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3390\/pharmaceutics13050592","article-title":"Recent progress and challenges for drug-resistant tuberculosis treatment","volume":"13","author":"Stephanie","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.micpath.2024.107074_bib125","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coph.2018.08.001","article-title":"The present state of the tuberculosis drug development pipeline","volume":"42","author":"Libardo","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.micpath.2024.107074_bib126","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02020-19","article-title":"OPC-167832, a novel carbostyril derivative with potent antituberculosis activity as a DPRE1 inhibitor","volume":"64","author":"Hariguchi","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2024.107074_bib127","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00583-21","article-title":"Comparative analysis of pharmacodynamics in the c3heb\/fej mouse tuberculosis model for DprE1 inhibitors TBA-7371, PBTZ169, and OPC-167832","volume":"65","author":"Robertson","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9 19","key":"10.1016\/j.micpath.2024.107074_bib128","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/nm.3262","article-title":"Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis","volume":"19","author":"Pethe","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.micpath.2024.107074_bib129","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1039\/D0MD00398K","article-title":"Structure guided generation of thieno[3,2- d ]pyrimidin-4-amine Mycobacterium tuberculosis bd oxidase inhibitors","volume":"12","author":"Hopfner","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.micpath.2024.107074_bib130","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/sj.clpt.6100362","article-title":"Advances in the treatment of tuberculosis","volume":"82","author":"Zhang","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.micpath.2024.107074_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.cimid.2020.101574","article-title":"Drug resistant Tuberculosis: a review","volume":"74","author":"Khawbung","year":"2021","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"10.1016\/j.micpath.2024.107074_bib132","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3390\/ph15050576","article-title":"New quinoline\u2013urea\u2013benzothiazole hybrids as promising antitubercular agents: synthesis, in vitro antitubercular activity, cytotoxicity studies, and in silico ADME profiling","volume":"15","author":"Besson","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.micpath.2024.107074_bib133","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s40265-022-01817-w","article-title":"The struggle to end a millennia-long pandemic: novel candidate and repurposed drugs for the treatment of tuberculosis","volume":"82","author":"Edwards","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.micpath.2024.107074_bib134","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2147\/IDR.S390187","article-title":"In vitro and intracellular antibacterial activity of sudapyridine (WX-081) against tuberculosis","author":"Xiao","year":"2023","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.micpath.2024.107074_bib135","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02477-21","article-title":"Sudapyridine (WX-081), a novel compound against Mycobacterium tuberculosis","volume":"10","author":"Yao","year":"2022","journal-title":"Microbiol. Spectr."},{"issue":"16 79","key":"10.1016\/j.micpath.2024.107074_bib136","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s40265-019-01207-9","article-title":"Pretomanid: first approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"issue":"1 8","key":"10.1016\/j.micpath.2024.107074_bib137","first-page":"1","article-title":"Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824)","volume":"8","author":"Baptista","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.micpath.2024.107074_bib139","author":"Vishwa"},{"key":"10.1016\/j.micpath.2024.107074_bib140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/2229-516X.112228","article-title":"Bedaquiline: first FDA-approved tuberculosis drug in 40 years","volume":"3","author":"Mahajan","year":"2013","journal-title":"Int J Appl Basic Med Res"},{"key":"10.1016\/j.micpath.2024.107074_bib141","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1473-3099(21)00470-9","article-title":"Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study","volume":"22","author":"Ismail","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2024.107074_bib142","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00621-2021","article-title":"Emergence of bedaquiline resistance in a high tuberculosis burden country","volume":"59","author":"Chesov","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.micpath.2024.107074_bib143","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1086\/508278","article-title":"Rifapentine for the treatment of pulmonary tuberculosis","volume":"43","author":"Munsiff","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.micpath.2024.107074_bib144","first-page":"11","article-title":"Therapeutics and Clinical Risk Management Dovepress the role of delamanid in the treatment of drug-resistant tuberculosis","author":"Sloan","year":"2015","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.micpath.2024.107074_bib145","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01608-21","article-title":"Population pharmacokinetic and concentration-QTc analysis of delamanid in pediatric participants with multidrug-resistant tuberculosis","volume":"66","author":"Sasaki","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2024.107074_bib146","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02144-21","article-title":"Delamanid added to an optimized background regimen in children with multidrug-resistant tuberculosis: results of a phase I\/II clinical trial","volume":"66","author":"Garcia-Prats","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2024.107074_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.jctube.2023.100382","article-title":"Trends in tuberculosis clinicians' adoption of short-course regimens for latent tuberculosis infection","author":"Feng","year":"2023","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"10.1016\/j.micpath.2024.107074_bib148","doi-asserted-by":"crossref","first-page":"e938","DOI":"10.1093\/cid\/ciac528","article-title":"Bedaquiline, delamanid, linezolid, and clofazimine for treatment of pre-extensively drug-resistant tuberculosis","volume":"76","author":"Padmapriyadarsini","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.micpath.2024.107074_bib149","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1183\/13993003.03492-2020","article-title":"Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model","volume":"58","author":"Heyckendorf","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.micpath.2024.107074_bib150","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1021\/acs.accounts.0c00878","article-title":"Strategies to combat multi-drug resistance in tuberculosis","volume":"54","author":"Singh","year":"2021","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.micpath.2024.107074_bib151","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.coph.2021.05.007","article-title":"Novel treatments in multidrug-resistant tuberculosis","volume":"59","author":"Mondoni","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.micpath.2024.107074_bib152","first-page":"815","article-title":"Bioenergetic inhibitors: antibiotic efficacy and mechanisms of action in Mycobacterium tuberculosis","author":"Hasenoehrl","year":"2021","journal-title":"Front Cell Infect Microbiol 0"},{"key":"10.1016\/j.micpath.2024.107074_bib153","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/14787210.2023.2240022","article-title":"New advances in the treatments of drug-resistant tuberculosis","volume":"21","author":"Mahmoud","year":"2023","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.micpath.2024.107074_bib154","doi-asserted-by":"crossref","first-page":"850","DOI":"10.4103\/0971-5916.92630","article-title":"Diagnosis & treatment of tuberculosis in HIV co-infected patients","volume":"134","author":"Padmapriyadarsini","year":"2011","journal-title":"Indian J. Med. Res."},{"issue":"2 14","key":"10.1016\/j.micpath.2024.107074_bib155","first-page":"491","article-title":"Mycobacterium tuberculosis-specific CD4 T cells expressing CD153 inversely associate with bacterial load and disease severity in human tuberculosis","volume":"14","author":"Du Bruyn","year":"2020","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.micpath.2024.107074_bib156","doi-asserted-by":"crossref","first-page":"696","DOI":"10.5588\/ijtld.21.0125","article-title":"Expanding the use of dolutegravir-based antiretroviral therapy in multidrug-resistant TB","volume":"25","author":"Murphy","year":"2021","journal-title":"Int. J. Tubercul. Lung Dis."},{"key":"10.1016\/j.micpath.2024.107074_bib157","article-title":"Preference of inhalants over pills\/injections among pulmonary tuberculosis patients in Western India: a cross-sectional study","volume":"23","author":"Nirmal","year":"2021","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"10.1016\/j.micpath.2024.107074_bib158","first-page":"1","article-title":"Nanotechnology-based approach in tuberculosis treatment","volume":"2017","author":"Nasiruddin","year":"2017","journal-title":"Tuberc Res Treat"},{"key":"10.1016\/j.micpath.2024.107074_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2023.105022","article-title":"Inhalation drug delivery in combating pulmonary infections: advances and challenges","author":"Kumbhar","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.micpath.2024.107074_bib160","first-page":"1790","article-title":"Host-directed therapy in tuberculosis: targeting host metabolism","volume":"1","author":"Dorhoi","year":"2020","journal-title":"Frontiers in Immunology | Www.Frontiersin.Org"},{"key":"10.1016\/j.micpath.2024.107074_bib161","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/imr.12951","article-title":"Host-directed therapy to combat mycobacterial infections","volume":"301","author":"Kilin\u00e7","year":"2021","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.micpath.2024.107074_bib162","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41577-022-00734-z","article-title":"Host-directed immunotherapy of viral and bacterial infections: past, present and future","volume":"23","author":"Wallis","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.micpath.2024.107074_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2020.104649","article-title":"Human gene expression profiling identifies key therapeutic targets in tuberculosis infection: a systematic network meta-analysis","volume":"87","author":"Alam","year":"2021","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.micpath.2024.107074_bib164","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1039\/D0CB00226G","article-title":"The pursuit of mechanism of action: uncovering drug complexity in TB drug discovery","volume":"2","author":"Yuan","year":"2021","journal-title":"RSC Chem. Biol"},{"key":"10.1016\/j.micpath.2024.107074_bib165","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.tube.2014.10.003","article-title":"Future target-based drug discovery for tuberculosis?","volume":"94","author":"Kana","year":"2014","journal-title":"Tuberculosis"}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401024005412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401024005412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:31:08Z","timestamp":1778542268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401024005412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":163,"alternative-id":["S0882401024005412"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2024.107074","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancements and challenges in tuberculosis drug discovery: A comprehensive overview","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2024.107074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107074"}}